Esperion Therapeutics (NASDAQ:ESPR) had its price objective boosted by investment analysts at JMP Securities from $60.00 to $153.00 in a research note issued to investors on Thursday, The Fly reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. JMP Securities’ price objective indicates a potential upside of 103.30% from the company’s previous close.
A number of other equities analysts also recently issued reports on the stock. BidaskClub raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 13th. UBS Group set a $88.00 price objective on shares of Esperion Therapeutics and gave the stock a “buy” rating in a report on Wednesday, January 17th. Credit Suisse Group initiated coverage on shares of Esperion Therapeutics in a report on Wednesday, January 17th. They issued an “outperform” rating and a $103.00 price objective on the stock. Chardan Capital raised their price objective on shares of Esperion Therapeutics from $20.00 to $75.00 and gave the stock a “neutral” rating in a report on Wednesday, December 6th. Finally, Needham & Company LLC raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and raised their price objective for the stock from $72.00 to $81.00 in a report on Thursday, December 14th. Seven analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Esperion Therapeutics has an average rating of “Buy” and a consensus price target of $87.36.
Shares of Esperion Therapeutics (ESPR) opened at $75.26 on Thursday. The stock has a market cap of $2,050.00, a PE ratio of -10.72 and a beta of 2.45. Esperion Therapeutics has a 1-year low of $20.39 and a 1-year high of $82.68.
In other Esperion Therapeutics news, Director Nicole Vitullo sold 11,674 shares of the firm’s stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $71.79, for a total transaction of $838,076.46. Following the sale, the director now owns 3,177 shares in the company, valued at approximately $228,076.83. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 32.50% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ESPR. Raymond James Financial Services Advisors Inc. bought a new stake in Esperion Therapeutics during the 4th quarter worth approximately $222,000. BB&T Securities LLC bought a new stake in shares of Esperion Therapeutics during the fourth quarter valued at approximately $263,000. First Mercantile Trust Co. raised its position in shares of Esperion Therapeutics by 56.0% during the fourth quarter. First Mercantile Trust Co. now owns 4,233 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 1,519 shares during the last quarter. Creative Planning bought a new stake in shares of Esperion Therapeutics during the fourth quarter valued at approximately $314,000. Finally, Oakmont Partners LLC bought a new stake in shares of Esperion Therapeutics during the fourth quarter valued at approximately $323,000. Institutional investors own 91.69% of the company’s stock.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.